Xoma Ltd (XOMA) 1.05 $XOMA
Vasculitis Pipeline Review, H2 2015 - 14 Companies & 12 Drug Profiles
M2 - Wed Oct 07, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxnvm5/vasculitis) has announced the addition of the "Vasculitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Aprogen, Inc. - ChemoCentryx, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hemostemix Ltd - K-Stemcell Co., Ltd. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Stempeutics Research Private Limited - Teijin Pharma Limited - XOMA Corporation Drug Profiles - ACP-01 - belimumab - beperminogene perplasmid - CCX-168 - gevokizumab - immune globulin (human) - Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - PF-1355 - rituximab biosimilar - Stempeucel - tocilizumab - Vascostem For more information visit http://www.researchandmarkets.com/research/pxnvm5/vasculitis
PFE: 34.05 (+0.72), CCXI: 7.15 (+0.30), GSK: 42.11 (+0.67), XOMA: 1.05 (+0.03)
Wall St. Analyst Announces Investment Opinion: Weekly Screener - Biotech Stocks Publication
Business Wire - Mon Oct 05, 8:00AM CDT
WallStAnalyst.com's (SEBI Reg. # INH200000147) (www.wallstanalyst.com) 'Weekly Screener' looks at the performance of the global stock markets and more as China's economic woes, risks of global growth contraction and weak data from the U.S. last Friday shape sentiments. Our analysts scrutinized last week's fundamental and markets events to pinpoint the reasons behind the biotech sector's roller coaster trading. Our coverage includes the following companies: Xenoport Inc. (NASDAQ: XNPT), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Amicus Therapeutics Inc. (NASDAQ: FOLD), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) and XOMA Corporation (NASDAQ: XOMA). Visit us for your free biotech companies coverage at:
MACK: 9.67 (+0.96), ARIA: 6.80 (-0.03), FOLD: 6.59 (+0.64), XOMA: 1.05 (+0.03), XNPT: 5.18 (+0.38)
XOMA Shoots up on Immuno-Oncology Deal with Novartis
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 5:21PM CDT
XOMA Corporation (XOMA) announced that it has entered into an exclusive license agreement with Novartis (NVS). Shares of XOMA were up 43.7% on the announcement.
ABT: 43.60 (+0.10), NVO: 55.72 (+2.07), XOMA: 1.05 (+0.03), NVS: 92.98 (+0.55)
XOMA (XOMA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 7:36AM CDT
XOMA (XOMA) Shares March Higher, Can It Continue?
XOMA: 1.05 (+0.03)
XOMA Announces Development and Commercialization Agreement for First-in-Class Anti-TGF-beta Antibody Program in Immuno-Oncology
GlobeNewswire - Thu Oct 01, 6:30AM CDT
-- $37.0 million upfront payment
XOMA: 1.05 (+0.03)
10 Worst NASDAQ Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:43PM CDT
The third quarter was brutal for biotech stocks. Here are the companies that fared the worst.
VSTM: 1.81 (-0.13), OREX: 2.96 (+0.09), TTPH: 8.82 (+0.25), IMMU: 2.39 (+0.09), RPTP: 5.61 (-0.14), CLDX: 13.27 (+0.53), THRX: 8.90 (+0.55), ARNA: 2.34 (+0.01), KPTI: 13.24 (+0.06), XOMA: 1.05 (+0.03)
Global Hypoglycemia Pipeline Review 2015 - 9 Companies & 7 Drug Profiles
M2 - Wed Sep 23, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j9b2m7/hypoglycemia) has announced the addition of the "Hypoglycemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypoglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biodel Inc. - Eli Lilly and Company - Heptares Therapeutics Limited - Novartis AG - SkyePharma Plc - USV Limited - XERIS Pharmaceuticals, Inc. - XOMA Corporation - Zealand Pharma A/S Drug Profiles - Biologic for Hypoglycemia - glucagon - pasireotide - Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia - terbutaline sulphate - XOMA-358 - ZP-4207 For more information visit http://www.researchandmarkets.com/research/j9...poglycemia
LLY: 78.31 (+1.33), BIOD: 0.37 (-0.02), XOMA: 1.05 (+0.03), NVS: 92.98 (+0.55)
Anterior Uveitis Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles
M2 - Wed Sep 23, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3v6gfv/anterior_uveitis) has announced the addition of the "Anterior Uveitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anterior Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - Aldeyra Therapeutics, Inc. - EyeGate Pharmaceuticals, Inc. - Kineta, Inc. - Neuroptis Biotech - Virogenomics, Inc. - XOMA Corporation Drug Profiles - dalazatide - dexamethasone acetate - dexamethasone sodium phosphate - gevokizumab - LME-636 - NOP-3 - NS-2 - Peptides to Modulate TCR for Uveitis For more information visit http://www.researchandmarkets.com/research/3v...or_uveitis
EYEG: 2.72 (-0.21), XOMA: 1.05 (+0.03)
Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells
PR Newswire - Mon Sep 21, 7:50AM CDT
Equity Research Institute has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research report on Exelixis can be accessed at https://www.erionline.net/EXEL.pdf On Friday, September 18, 2015, the NASDAQ Composite ended at 4,827.23, down 1.36%, the Dow Jones Industrial Average declined 1.74%, to finish the day at 16,384.79, and the S&P 500 closed at 1,958.03, down 1.62%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
ENZN: 0.84 (+0.01), STEM: 0.40 (unch), PPHM: 1.07 (+0.01), XOMA: 1.05 (+0.03), EXEL: 5.79 (+0.22)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Xoma Corporation and a Lead Plaintiff Deadline of September 22, 2015 - XOMA
GlobeNewswire - Fri Sep 11, 2:10PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Xoma Corporation (NASDAQ:XOMA) securities between November 6, 2014 and July 21, 2015.
XOMA: 1.05 (+0.03)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against XOMA Corporation and Lead Plaintiff Deadline September 22, 2015
PR Newswire - Tue Sep 08, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the Northern District of California on behalf of those who purchased shares of XOMA Corporation ("XOMA" or the "Company"
(NasdaqGM: XOMA), during the period between November 6, 2014 and July 21, 2015 inclusive. (the "Class Period" .
XOMA: 1.05 (+0.03)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Xoma Corporation -- XOMA
GlobeNewswire - Thu Sep 03, 4:55PM CDT
Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Xoma Corporation (NASDAQ:XOMA) securities during the period from November 6, 2014 through July 21, 2015. The lawsuit seeks to recover damages for Xoma Corporation investors under the federal securities laws.
XOMA: 1.05 (+0.03)
Acute Coronary Syndrome - Pipeline Review, H2 2015
M2 - Fri Aug 21, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mpxwl6/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - advanceCor - Arena Pharmaceuticals - Artery Therapeutics - Athera Biotechnologies - Bayer - Cardiome Pharma - Cerenis Therapeutics - Esperion Therapeutics - GlaxoSmithKline - Lee's Pharmaceutical - MedImmune - Pfizer - Teva Pharmaceutical Industries - The Medicines Company - Vitae Pharmaceuticals - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/mp...e_coronary
ESPR: 22.38 (+0.03), VTAE: 11.60 (+0.04), TEVA: 59.55 (+3.59), GSK: 42.11 (+0.67), ARNA: 2.34 (+0.01), XOMA: 1.05 (+0.03)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Thu Aug 20, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
WFM: 32.28 (-0.25), IDI: 6.78 (+0.55), MDCA: 21.93 (-0.30), WMS: 31.17 (+0.04), PAA: 31.32 (-0.16), TNET: 19.90 (+0.59), VDSI: 18.09 (+0.41), SWI: 57.96 (-0.03), ONDK: 9.31 (+0.07), HILL: 9.75 (unch), ITG: 15.97 (+0.30), EZPW: 6.59 (+0.23), SOCB: 13.26 (-0.17), ABGB: 4.77 (+0.08), LOCK: 9.65 (+0.23), PLNR: 6.30 (+0.02), ZU: 17.40 (-0.06), XOMA: 1.05 (+0.03), CTCT: 25.73 (+0.78)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Xoma Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of September 22, 2015 -- XOMA
GlobeNewswire - Wed Aug 19, 12:14PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
XOMA: 1.05 (+0.03)
TRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors of Important Deadline in Class Action - XOMA
Business Wire - Tue Aug 18, 9:30AM CDT
The Rosen Law Firm, a global investor rights firm, reminds purchasers of Xoma Corporation (NASDAQ:XOMA) securities during the period from November 6, 2014 through July 21, 2015 of the important September 22, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Xoma Corporation investors under the federal securities laws.
XOMA: 1.05 (+0.03)
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in XOMA Corporation to Contact the Firm
Marketwired - Fri Aug 14, 1:38PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in XOMA Corporation ("XOMA" or the "Company" (NASDAQ: XOMA) of the September 22, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
XOMA: 1.05 (+0.03)
Guidance & Quarterly Review on Four Biotech Companies
ACCESSWIRE - Fri Aug 14, 6:00AM CDT
NEW YORK, NY / ACCESSWIRE / August 14, 2015 / Four biotechnology companies reported earnings last week. These companies include Synta Pharmaceuticals (NASDAQ: SNTA), TransEnterix, Inc., (NYSE-MKT: TRXC), Xoma Corp (NASDAQ: XOMA) and Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN).
ENZN: 0.84 (+0.01), SNTA: 0.67 (unch), TRXC: 2.50 (+0.03), XOMA: 1.05 (+0.03)
XOMA to Present at the 2015 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Fri Aug 07, 12:55PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the Company's Chief Executive Officer, is scheduled to present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015, at 2:30 p.m. EDT.
XOMA: 1.05 (+0.03)
Xoma reports 2Q loss
Automated Insights - Thu Aug 06, 6:39PM CDT
BERKELEY, Calif. (AP) _ Xoma Corp. (XOMA) on Thursday reported a loss of $23.8 million in its second quarter.
XOMA: 1.05 (+0.03)
Vasculitis Pipeline Review, H2 2015 - 14 Companies & 12 Drug Profiles
M2 - Wed Oct 07, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxnvm5/vasculitis) has announced the addition of the "Vasculitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Aprogen, Inc. - ChemoCentryx, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hemostemix Ltd - K-Stemcell Co., Ltd. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Stempeutics Research Private Limited - Teijin Pharma Limited - XOMA Corporation Drug Profiles - ACP-01 - belimumab - beperminogene perplasmid - CCX-168 - gevokizumab - immune globulin (human) - Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - PF-1355 - rituximab biosimilar - Stempeucel - tocilizumab - Vascostem For more information visit http://www.researchandmarkets.com/research/pxnvm5/vasculitis
PFE: 34.05 (+0.72), CCXI: 7.15 (+0.30), GSK: 42.11 (+0.67), XOMA: 1.05 (+0.03)
Wall St. Analyst Announces Investment Opinion: Weekly Screener - Biotech Stocks Publication
Business Wire - Mon Oct 05, 8:00AM CDT
WallStAnalyst.com's (SEBI Reg. # INH200000147) (www.wallstanalyst.com) 'Weekly Screener' looks at the performance of the global stock markets and more as China's economic woes, risks of global growth contraction and weak data from the U.S. last Friday shape sentiments. Our analysts scrutinized last week's fundamental and markets events to pinpoint the reasons behind the biotech sector's roller coaster trading. Our coverage includes the following companies: Xenoport Inc. (NASDAQ: XNPT), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Amicus Therapeutics Inc. (NASDAQ: FOLD), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) and XOMA Corporation (NASDAQ: XOMA). Visit us for your free biotech companies coverage at:
MACK: 9.67 (+0.96), ARIA: 6.80 (-0.03), FOLD: 6.59 (+0.64), XOMA: 1.05 (+0.03), XNPT: 5.18 (+0.38)
XOMA Shoots up on Immuno-Oncology Deal with Novartis
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 5:21PM CDT
XOMA Corporation (XOMA) announced that it has entered into an exclusive license agreement with Novartis (NVS). Shares of XOMA were up 43.7% on the announcement.
ABT: 43.60 (+0.10), NVO: 55.72 (+2.07), XOMA: 1.05 (+0.03), NVS: 92.98 (+0.55)
XOMA (XOMA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 7:36AM CDT
XOMA (XOMA) Shares March Higher, Can It Continue?
XOMA: 1.05 (+0.03)
XOMA Announces Development and Commercialization Agreement for First-in-Class Anti-TGF-beta Antibody Program in Immuno-Oncology
GlobeNewswire - Thu Oct 01, 6:30AM CDT
-- $37.0 million upfront payment
XOMA: 1.05 (+0.03)
10 Worst NASDAQ Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:43PM CDT
The third quarter was brutal for biotech stocks. Here are the companies that fared the worst.
VSTM: 1.81 (-0.13), OREX: 2.96 (+0.09), TTPH: 8.82 (+0.25), IMMU: 2.39 (+0.09), RPTP: 5.61 (-0.14), CLDX: 13.27 (+0.53), THRX: 8.90 (+0.55), ARNA: 2.34 (+0.01), KPTI: 13.24 (+0.06), XOMA: 1.05 (+0.03)
Global Hypoglycemia Pipeline Review 2015 - 9 Companies & 7 Drug Profiles
M2 - Wed Sep 23, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j9b2m7/hypoglycemia) has announced the addition of the "Hypoglycemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypoglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biodel Inc. - Eli Lilly and Company - Heptares Therapeutics Limited - Novartis AG - SkyePharma Plc - USV Limited - XERIS Pharmaceuticals, Inc. - XOMA Corporation - Zealand Pharma A/S Drug Profiles - Biologic for Hypoglycemia - glucagon - pasireotide - Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia - terbutaline sulphate - XOMA-358 - ZP-4207 For more information visit http://www.researchandmarkets.com/research/j9...poglycemia
LLY: 78.31 (+1.33), BIOD: 0.37 (-0.02), XOMA: 1.05 (+0.03), NVS: 92.98 (+0.55)
Anterior Uveitis Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles
M2 - Wed Sep 23, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3v6gfv/anterior_uveitis) has announced the addition of the "Anterior Uveitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anterior Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - Aldeyra Therapeutics, Inc. - EyeGate Pharmaceuticals, Inc. - Kineta, Inc. - Neuroptis Biotech - Virogenomics, Inc. - XOMA Corporation Drug Profiles - dalazatide - dexamethasone acetate - dexamethasone sodium phosphate - gevokizumab - LME-636 - NOP-3 - NS-2 - Peptides to Modulate TCR for Uveitis For more information visit http://www.researchandmarkets.com/research/3v...or_uveitis
EYEG: 2.72 (-0.21), XOMA: 1.05 (+0.03)
Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells
PR Newswire - Mon Sep 21, 7:50AM CDT
Equity Research Institute has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research report on Exelixis can be accessed at https://www.erionline.net/EXEL.pdf On Friday, September 18, 2015, the NASDAQ Composite ended at 4,827.23, down 1.36%, the Dow Jones Industrial Average declined 1.74%, to finish the day at 16,384.79, and the S&P 500 closed at 1,958.03, down 1.62%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
ENZN: 0.84 (+0.01), STEM: 0.40 (unch), PPHM: 1.07 (+0.01), XOMA: 1.05 (+0.03), EXEL: 5.79 (+0.22)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Xoma Corporation and a Lead Plaintiff Deadline of September 22, 2015 - XOMA
GlobeNewswire - Fri Sep 11, 2:10PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Xoma Corporation (NASDAQ:XOMA) securities between November 6, 2014 and July 21, 2015.
XOMA: 1.05 (+0.03)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against XOMA Corporation and Lead Plaintiff Deadline September 22, 2015
PR Newswire - Tue Sep 08, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the Northern District of California on behalf of those who purchased shares of XOMA Corporation ("XOMA" or the "Company"
(NasdaqGM: XOMA), during the period between November 6, 2014 and July 21, 2015 inclusive. (the "Class Period" . XOMA: 1.05 (+0.03)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Xoma Corporation -- XOMA
GlobeNewswire - Thu Sep 03, 4:55PM CDT
Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Xoma Corporation (NASDAQ:XOMA) securities during the period from November 6, 2014 through July 21, 2015. The lawsuit seeks to recover damages for Xoma Corporation investors under the federal securities laws.
XOMA: 1.05 (+0.03)
Acute Coronary Syndrome - Pipeline Review, H2 2015
M2 - Fri Aug 21, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mpxwl6/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - advanceCor - Arena Pharmaceuticals - Artery Therapeutics - Athera Biotechnologies - Bayer - Cardiome Pharma - Cerenis Therapeutics - Esperion Therapeutics - GlaxoSmithKline - Lee's Pharmaceutical - MedImmune - Pfizer - Teva Pharmaceutical Industries - The Medicines Company - Vitae Pharmaceuticals - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/mp...e_coronary
ESPR: 22.38 (+0.03), VTAE: 11.60 (+0.04), TEVA: 59.55 (+3.59), GSK: 42.11 (+0.67), ARNA: 2.34 (+0.01), XOMA: 1.05 (+0.03)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Thu Aug 20, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
WFM: 32.28 (-0.25), IDI: 6.78 (+0.55), MDCA: 21.93 (-0.30), WMS: 31.17 (+0.04), PAA: 31.32 (-0.16), TNET: 19.90 (+0.59), VDSI: 18.09 (+0.41), SWI: 57.96 (-0.03), ONDK: 9.31 (+0.07), HILL: 9.75 (unch), ITG: 15.97 (+0.30), EZPW: 6.59 (+0.23), SOCB: 13.26 (-0.17), ABGB: 4.77 (+0.08), LOCK: 9.65 (+0.23), PLNR: 6.30 (+0.02), ZU: 17.40 (-0.06), XOMA: 1.05 (+0.03), CTCT: 25.73 (+0.78)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Xoma Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of September 22, 2015 -- XOMA
GlobeNewswire - Wed Aug 19, 12:14PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
XOMA: 1.05 (+0.03)
TRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors of Important Deadline in Class Action - XOMA
Business Wire - Tue Aug 18, 9:30AM CDT
The Rosen Law Firm, a global investor rights firm, reminds purchasers of Xoma Corporation (NASDAQ:XOMA) securities during the period from November 6, 2014 through July 21, 2015 of the important September 22, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Xoma Corporation investors under the federal securities laws.
XOMA: 1.05 (+0.03)
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in XOMA Corporation to Contact the Firm
Marketwired - Fri Aug 14, 1:38PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in XOMA Corporation ("XOMA" or the "Company"
(NASDAQ: XOMA) of the September 22, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. XOMA: 1.05 (+0.03)
Guidance & Quarterly Review on Four Biotech Companies
ACCESSWIRE - Fri Aug 14, 6:00AM CDT
NEW YORK, NY / ACCESSWIRE / August 14, 2015 / Four biotechnology companies reported earnings last week. These companies include Synta Pharmaceuticals (NASDAQ: SNTA), TransEnterix, Inc., (NYSE-MKT: TRXC), Xoma Corp (NASDAQ: XOMA) and Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN).
ENZN: 0.84 (+0.01), SNTA: 0.67 (unch), TRXC: 2.50 (+0.03), XOMA: 1.05 (+0.03)
XOMA to Present at the 2015 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Fri Aug 07, 12:55PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the Company's Chief Executive Officer, is scheduled to present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015, at 2:30 p.m. EDT.
XOMA: 1.05 (+0.03)
Xoma reports 2Q loss
Automated Insights - Thu Aug 06, 6:39PM CDT
BERKELEY, Calif. (AP) _ Xoma Corp. (XOMA) on Thursday reported a loss of $23.8 million in its second quarter.
XOMA: 1.05 (+0.03)
